Assessing Functional Performance in the Mdx Mouse Model

被引:131
作者
Aartsma-Rus, Annemieke [1 ]
van Putten, Maaike [1 ]
机构
[1] Leiden Univ, Med Ctr, Dept Human Genet, NL-2300 RA Leiden, Netherlands
来源
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS | 2014年 / 85期
关键词
Behavior; Issue; 85; Duchenne muscular dystrophy; neuromuscular disorders; outcome measures; functional testing; mouse model; grip strength; hanging test wire; hanging test grid; rotarod running; treadmill running; DUCHENNE MUSCULAR-DYSTROPHY; MICE; MUSCLE; RESTORATION; DEFICIENT; STRENGTH; PROTOCOL; THERAPY;
D O I
10.3791/51303
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
070301 [无机化学]; 070403 [天体物理学]; 070507 [自然资源与国土空间规划学]; 090105 [作物生产系统与生态工程];
摘要
Duchenne muscular dystrophy (DMD) is a severe and progressive muscle wasting disorder for which no cure is available. Nevertheless, several potential pharmaceutical compounds and gene therapy approaches have progressed into clinical trials. With improvement in muscle function being the most important end point in these trials, a lot of emphasis has been placed on setting up reliable, reproducible, and easy to perform functional tests to pre clinically assess muscle function, strength, condition, and coordination in the mdx mouse model for DMD. Both invasive and noninvasive tests are available. Tests that do not exacerbate the disease can be used to determine the natural history of the disease and the effects of therapeutic interventions (e.g. forelimb grip strength test, two different hanging tests using either a wire or a grid and rotarod running). Alternatively, forced treadmill running can be used to enhance disease progression and/or assess protective effects of therapeutic interventions on disease pathology. We here describe how to perform these most commonly used functional tests in a reliable and reproducible manner. Using these protocols based on standard operating procedures enables comparison of data between different laboratories.
引用
收藏
页数:11
相关论文
共 21 条
[1]
Function and genetics of dystrophin and dystrophin-related proteins in muscle [J].
Blake, DJ ;
Weir, A ;
Newey, SE ;
Davies, KE .
PHYSIOLOGICAL REVIEWS, 2002, 82 (02) :291-329
[2]
Phase 1 Gene Therapy for Duchenne Muscular Dystrophy Using a Translational Optimized AAV Vector [J].
Bowles, Dawn E. ;
McPhee, Scott W. J. ;
Li, Chengwen ;
Gray, Steven J. ;
Samulski, Jade J. ;
Camp, Angelique S. ;
Li, Juan ;
Wang, Bing ;
Monahan, Paul E. ;
Rabinowitz, Joseph E. ;
Grieger, Joshua C. ;
Govindasamy, Lakshmanan ;
Agbandje-McKenna, Mavis ;
Xiao, Xiao ;
Samulski, R. Jude .
MOLECULAR THERAPY, 2012, 20 (02) :443-455
[3]
X-CHROMOSOME-LINKED MUSCULAR-DYSTROPHY (MDX) IN THE MOUSE [J].
BULFIELD, G ;
SILLER, WG ;
WIGHT, PAL ;
MOORE, KJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1984, 81 (04) :1189-1192
[4]
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management [J].
Bushby, Katharine ;
Finkel, Richard ;
Birnkrant, David J. ;
Case, Laura E. ;
Clemens, Paula R. ;
Cripe, Linda ;
Kaul, Ajay ;
Kinnett, Kathi ;
McDonald, Craig ;
Pandya, Shree ;
Poysky, James ;
Shapiro, Frederic ;
Tomezsko, Jean ;
Constantin, Carolyn .
LANCET NEUROLOGY, 2010, 9 (01) :77-93
[5]
Early development of synchronized walking on the rotorod in rats - Effects of training and handling [J].
Chapillon, P ;
Lalonde, R ;
Jones, N ;
Caston, J .
BEHAVIOURAL BRAIN RESEARCH, 1998, 93 (1-2) :77-81
[6]
Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study [J].
Cirak, Sebahattin ;
Arechavala-Gomeza, Virginia ;
Guglieri, Michela ;
Feng, Lucy ;
Torelli, Silvia ;
Anthony, Karen ;
Abbs, Stephen ;
Garralda, Maria Elena ;
Bourke, John ;
Wells, Dominic J. ;
Dickson, George ;
Wood, Matthew J. A. ;
Wilton, Steve D. ;
Straub, Volker ;
Kole, Ryszard ;
Shrewsbury, Stephen B. ;
Sewry, Caroline ;
Morgan, Jennifer E. ;
Bushby, Kate ;
Muntoni, Francesco .
LANCET, 2011, 378 (9791) :595-605
[7]
Three mouse models of muscular dystrophy:: the natural history of strength and fatigue in dystrophin-, dystrophin/utrophin-, and laminin α2-deficient mice [J].
Connolly, AM ;
Keeling, RM ;
Mehta, S ;
Pestronk, A ;
Sanes, JR .
NEUROMUSCULAR DISORDERS, 2001, 11 (08) :703-712
[8]
Gentamicin treatment in exercised mdx mice: Identification of dystrophin-sensitive pathways and evaluation of efficacy in work-loaded dystrophic muscle [J].
De Luca, Annamaria ;
Nico, Beatrice ;
Rolland, Jean-Francois ;
Cozzoli, Anna ;
Burdi, Rosa ;
Mangieri, Domenica ;
Giannuzzi, Viviana ;
Liantonio, Antonella ;
Cippone, Valentina ;
De Bellis, Michela ;
Nicchia, Grazia Paola ;
Camerino, Giulia Maria ;
Frigeri, Antonio ;
Svelto, Maria ;
Camerino, Diana Conte .
NEUROBIOLOGY OF DISEASE, 2008, 32 (02) :243-253
[9]
Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy [J].
Goemans, Nathalie M. ;
Tulinius, Mar ;
van den Akker, Johanna T. ;
Burm, Brigitte E. ;
Ekhart, Peter F. ;
Heuvelmans, Niki ;
Holling, Tjadine ;
Janson, Anneke A. ;
Platenburg, Gerard J. ;
Sipkens, Jessica A. ;
Sitsen, J. M. Ad ;
Aartsma-Rus, Annemieke ;
van Ommen, Gert-Jan B. ;
Buyse, Gunnar ;
Darin, Niklas ;
Verschuuren, Jan J. ;
Campion, Giles V. ;
de Kimpe, Sjef J. ;
van Deutekom, Judith C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (16) :1513-1522
[10]
DYSTROPHIN - THE PROTEIN PRODUCT OF THE DUCHENNE MUSCULAR-DYSTROPHY LOCUS [J].
HOFFMAN, EP ;
BROWN, RH ;
KUNKEL, LM .
CELL, 1987, 51 (06) :919-928